The SEARCH study ascertained individuals with type 2 diabetes (T2D) diagnosed at <20 years of age at 5 study centers in the US from 2002 to 2018 and calculated annual incidence as number of cases divided by the population <20 years in the catchment area (∼5 million annually based on US Census or health-plan member counts) . We estimated incidence trends using a generalized autoregressive (2-year) moving average model. From annual incidence, we calculated peak age at T2D diagnosis overall population and within period, sex, race and ethnicity strata. Incidence increased from 2002-2009 to 2010-2018 (p<0.0001) ; however, the peak age at diagnosis did not change (16 years; Figure) . Across all years, the peak age at diagnosis was similar between females (16 years [95% CI 15-18]) and males (16 years [16-18]) . The peak age at diagnosis was younger for non-Hispanic Black youth (NHB; 13 years) , while similar for American Indian (AI) , Asian and Pacific Islander (API) , Hispanic (HISP) , and non-Hispanic White (NHW) youth (16 years; Figure) . These data indicate continued increases in T2D incidence across ages associated with the pubertal transition, with a rapid decline following the incidence peak. They also highlight an earlier T2D onset among NHB youth. These results highlight the need for pre-pubertal or early pubertal intervention to mitigate risk of youth-onset T2D.


K. A. Sauder: None. A. Bellatorre: None. J. M. Lawrence: None. J. Divers: None. E. T. Jensen: Consultant; Regeneron Pharmaceuticals Inc. L. E. Wagenknecht: None. A. D. Liese: None. D. Dabelea: None. S. M. Marcovina: None. C. Pihoker: None. K. Reynolds: Research Support; Amgen Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation. A. S. Shah: None. L. M. Dolan: None.


Centers for Disease Control and Prevention and National Institutes of Health

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at